tiprankstipranks
Trending News
More News >

Kyverna Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Kyverna Therapeutics (KYTX) to Buy from Neutral with a $5 price target The company is set to produce three sets of data through mid-2025, with potential opportunity to demonstrate success across three KYV-101 pipeline programs, the analyst tells investors in a research note. Ahead of the three catalysts, the firm thinks the stock’s risk/reward profile attractive, “particularly given a deeply negative enterprise value.”

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue